Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Immunol Methods. 2018 Aug 8;461:37–43. doi: 10.1016/j.jim.2018.08.002

Table 1.

Pneumococcal vaccines, with summaries of current ACIP recommendations for use.

Vaccine Year licensed Serotypes included Indications
PPV23 (Pneumovax 23, Merck) 1983 1, 2, 3, 4, 5, 6B, 7F, 8, 9V, 9N, 10A, 11 A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F

  • Adults >65 years old (in series with PCV13)

  • Adults ages 19–64 with certain chronic medical conditions*

  • Infants/children at increased risk for pneumococcal disease (following administration of PCV13)
PCV7 (Prevnar, Pfizer) 2000 4, 6B, 9V, 14, 18C, 19F, 23F N/A+
PCV10 (Synflorix, GlaxoSmithKline) 2008 PCV7 serotypes + 1, 5,7F N/A+
PCV13 (Prevnar 13, Pfizer) 2009 PCV10 serotypes + 3, 6A, 19A

  • Infants

  • Adults >65 years old (in series with PPV23)

  • Adults ages 19–64 with immunocompromising conditions# (in series with PPV23)
*

Chronic medical conditions include chronic heart/lung/liver disease, diabetes mellitus, alcoholism, cigarette smoking

+

While used in other countries, PCV10 was not implemented in US immunization guidelines and PCV7 was directly replaced by PCV13

#

As well as adults with asplenia, CSF leaks, cochlear implants